Nakai Y, Furuse K, Ohta M, Yamaguchi Y, Fujii M, Asakawa M, Fukuoka M, Yoshida K, Niitani H
Sendai Kosei Hospital, Japan.
Acta Oncol. 1994;33(5):523-6. doi: 10.3109/02841869409083929.
Oral BOF-A2 (Emitefur), a new derivative of 5-fluorouracil (5-FU) containing both 1-ethoxymethyl-5-FU (EMFU), a masked form of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation, was administered to 71 non-small cell lung cancer (NSCLC) patients in a multi-center phase II study. The patients were scheduled to receive at least 2 courses of treatment, each consisting of 200 mg twice daily for 2 weeks followed by a 2-week rest period. Out of 62 evaluable patients, 11 (18%) responded (8 of 44 adeno- and 3 of 15 squamous cell carcinomas). Thirty-four patients showed no change and 17 progressive disease. The incidences of grade > or = 2 hematologic toxicity were 5-8% for leukopenia, thrombocytopenia, and anemia. The incidences of non-hematologic toxicity of grade > or = 2, such as anorexia, nausea/vomiting, and diarrhea, were close to 20% or lower.
口服BOF-A2（依米替氟）是5-氟尿嘧啶（5-FU）的一种新衍生物，含有5-FU的一种掩蔽形式1-乙氧甲基-5-FU（EMFU）和5-FU降解抑制剂3-氰基-2,6-二羟基吡啶（CNDP）。在一项多中心II期研究中，对71例非小细胞肺癌（NSCLC）患者给予了该药物。患者计划接受至少2个疗程的治疗，每个疗程包括每天2次，每次200mg，持续2周，随后休息2周。在62例可评估患者中，11例（18%）有反应（44例腺癌中有8例，15例鳞癌中有3例）。34例患者病情无变化，17例病情进展。白细胞减少、血小板减少和贫血的≥2级血液学毒性发生率为5-8%。≥2级非血液学毒性，如厌食、恶心/呕吐和腹泻的发生率接近20%或更低。
